–
Speakers
MS
Mary Sano, PhD – Professor of Psychiatry, Icahn School of Medicine at Mount Sinai; Director, Alzheimer's Disease Research Center
About the Talk
As the world becomes more technical and the population ages and expects to live longer, it is critically important that maintaining cognitive health become a lifelong commitment. Researchers have made great strides in understanding the biology of Alzheimer’s Disease and learning how to detect and even treat it at the earliest stages when they expect treatment to be most effective. Less success has been made with other forms of cognitive impairment and dementia but the research on brain health is not diagnostic specific and has identified lifestyle factors and behaviors of personal choice that can help support mental and cognitive health regardless of age or condition. This presentation will provide an update on the progress of treating and preventing Alzheimer’s dementia. It will examine some of the new challenges arising from this progress. It will examine some non-cognitive risks to functional decline in those with dementia and it will describe how to integrate what we know about brain health to maximize our function through all stages and ages of cognitive health.
Frontiers of BrainHealth is a hybrid speaker series. By registering for the season, you get a link to virtual talks as well as recordings. If you are interested in attending any talks in person, you can confirm in-person attendance when we send a reminder email a few days prior to each talk.
For more information, visit our FAQs or email brainhealthevents@utdallas.edu.
Dr. Mary Sano is professor of psychiatry at the Icahn School of Medicine at Mount Sinai, director of the Alzheimer’s Disease Research Center, and this year’s recipient of the lifetime achievement award from the Alzheimer's Association and the International Psychogeriatric Association's (IPA) Service Achievement Award.
As a neuropsychologist she has designed and conducted many clinical trials for the treatment and prevention of ADRD and cognitive decline in the elderly. She is the co-chair of the collaboration between IPA and Industry to define, detect, treat and manage Neuropsychiatric Symptoms in (NPS) in neurodegenerative cognitive disorders including dementia and mild cognitive impairment. She is the lead author on the IPA criteria for agitation which has been used to achieve regulatory approval for treatments for agitation. Her work includes scholarly examination of the detection of apathy across different dementias and its impact on functional capacity and on the economic consequences of cognitive impairment in aging. She has developed and evaluated tools for home assessment of cognition, and tools to measure the impact of cognitive impairment on employment and resource use. She is the lead author of several hundred publications, has trained many young investigators and consulted for multiple pharmaceutical companies on design and interpretation of clinical trials.
We are located at 2200 West Mockingbird Lane Dallas, TX 75235
The entrance to the surface parking lot is on Forest Park Road. The talks will be held in the Brain Performance Institute building, the second building when you enter through the gate.